Xinxing Li

Dr. Xinxing Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
XLXinxing Li
Xinxing Li
TLTao Liu
Tao Liu
ABAntonella Bacchiocchi
Antonella Bacchiocchi
MLMengxing Li
Mengxing Li
WCWen Cheng
Wen Cheng
ZHZhiqian Hu
Zhiqian Hu
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technology that enables genome-wide error correction at single read-level, achieving an error rate of 4.2 × 10 −7 , which is about two orders of magnitude lower than a read-centric de-noising method. The application of AccuScan to MRD demonstrated analytical sensitivity down to 10 −6 circulating variant allele frequency at 99% sample-level specificity. AccuScan showed 90% landmark sensitivity (within 6 weeks after surgery) and 100% specificity for predicting relapse in colorectal cancer. It also showed 67% sensitivity and 100% specificity in esophageal cancer using samples collected within one week after surgery. When AccuScan was applied to monitor immunotherapy in melanoma patients, the circulating tumor DNA (ctDNA) levels and dynamic profiles were consistent with clinical outcomes. Overall, AccuScan provides a highly accurate WGS solution for MRD detection, empowering ctDNA detection at parts per million range without requiring high sample input or personalized reagents.

29 June 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JSJie Yun Shi
Jie Yun Shi
YFYu-Xiang Fang
Yu-Xiang Fang
TTTong-Guan Tian
Tong-Guan Tian
WCWei-Ping Chen
Wei-Ping Chen
QSQiang Sun
Qiang Sun
XLXinxing Li
Xinxing Li
Background: We aimed to evaluate whether extracellular vesicles (EV)-derived microRNAs (miRNAs) can be used as biomarkers for advanced adenoma (AA) and colorectal cancer (CRC). Methods: We detected the changes in the plasma EV-delivered miRNA profiles in healthy donor (HD), AA patient, and I-II stage CRC patient groups using miRNA deep sequencing assay. We performed the TaqMan miRNA assay using 173 plasma samples (two independent cohorts) from HDs, AA patients, and CRC patients to identify the candidate miRNA(s). The accuracy of candidate miRNA(s) in diagnosing AA and CRC was determined using the area under the receiver-operating characteristic curve (AUC) values. Logistic regression analysis was performed to evaluate the association of candidate miRNA(s) as an independent factor for the diagnosis of AA and CRC. The role of candidate miRNA(s) in the malignant progression of CRC was explored using functional assays. Results: We screened and identified four prospective EV-delivered miRNAs, including miR-185-5p, which were significantly upregulated or downregulated in AA vs. HD and CRC vs. AA groups. In two independent cohorts, miR-185-5p was the best potential biomarker with the AUCs of 0.737 (Cohort I) and 0.720 (Cohort II) for AA vs. HD diagnosis, 0.887 (Cohort I) and 0.803 (Cohort II) for CRC vs. HD diagnosis, and 0.700 (Cohort I) and 0.631 (Cohort II) for CRC vs. AA diagnosis. Finally, we demonstrated that the upregulated expression of miR-185-5p promoted the malignant progression of CRC. Conclusion: EV-delivered miR-185-5p in the plasma of patients is a promising diagnostic biomarker for colorectal AA and CRC. Trial registration The study protocol was approved by the Ethics Committee of Changzheng Hospital, Naval Medical University, China (Ethics No. 2022SL005, Registration No. of China Clinical Trial Registration Center: ChiCTR220061592).

12 December 2022 in Frontiers in Genetics
Verified
Journal Article
Open access
SWShuxun Wei
Shuxun Wei
QSQiang Sun
Qiang Sun
JCJinshui Chen
Jinshui Chen
XLXinxing Li
Xinxing Li
ZHZhiqian Hu
Zhiqian Hu
Background: Although mRNA vaccines have been effective against multiple cancers, their efficacy against stomach adenocarcinoma (STAD) remains undefined. Immunotyping can indicate the comprehensive immune status in tumors and their immune microenvironment, which is closely associated with therapeutic response and vaccination potential. The aim of this study was to identify potential antigens in STAD for mRNA vaccine development, and further distinguish immune subtypes of STAD to construct an immune landscape for selecting suitable patients for vaccination.Methods: The gene expression and clinicopathological features of patients with gastric cancer were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression Program (GTEx). 729 samples from GSE66229 and GSE84437 were downloaded through GEO and were used as the validation cohorts. Differential gene expression, genetic alterations and prognosis were analyzed using the R package, cBioPortal program and Kaplan-Meier. The relationship between tumor antigens and immune cells was evaluated and plotted by TIMER. ConsensusClusterPlus was used for consistency matrix construction and data clustering, and graph learning-based dimensional reduction was used to depict immune landscape. WGCNA was used to estimate the relationship between the color modules and immune subtypes.Results: Two overexpressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in STAD, including RAI14 and NREP. The immune subtypes showed distinct molecular, cellular and clinical characteristics. IS1 and IS2 exhibited immune-activated phenotypes and correlated to better survival compared to IS3, while IS3 tumors was immunologically cold. Immunogenic cell death modulators, immune checkpoints, and CA125, and CEA were also differentially expressed among the three immune subtypes. Finally, the immune landscape of STAD showed a high degree of heterogeneity between individual patients.Conclusion: RAI14 and NREP are potential antigens for developing anti-STAD mRNA vaccine, and patients with IS1 and IS3 tumors may be suitable for vaccination.

18 December 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
XYXiaomao Yin
Xiaomao Yin
JWJinran Wu
Jinran Wu
MXMi-Die Xu
Mi-Die Xu
TTTongguan Tian
Tongguan Tian
LZLin Zhu
Lin Zhu
ZHZhiqian Hu
Zhiqian Hu
The efficacy of immune checkpoint inhibitors (ICIs) in microsatellite stable colorectal cancer (MSS CRC) remains limited, highlighting an urgent need for p

14 March 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
QSQiang Sun
Qiang Sun
YSYunjie Shi
Yunjie Shi
XLXiaoben Liang
Xiaoben Liang
HLHao Lu
Hao Lu
YHYu Huang
Yu Huang
XLXinxing Li
Xinxing Li
Background: Diversion colitis (DC) is nonspecific inflammation of the distal intestinal mucosa following disruption of colonic continuity with colonic dysfunction. The colonscopic score is a good tool for differentiating the severity of patients with DC. At present, no studies have analyzed the pathogenesis of DC from the perspective of the diversity and and differences of intestinal flora.Methods: Retrospective study: Clinical information were collected from patients with low rectal cancer admitted to the Department of Anorectal Surgery, Changzheng Hospital, from April 2017 to April 2019. These patients underwent laparoscopic low anterior resection (LAR) combined with terminal ileum enterostomy (dual-chamber). We used chi-square test to comparethe clinical baseline information, clinical symptoms, and colonscopic characteristics between different severity of DC. Propsective oberservational study: We recruited 40 patients with laparoscopic anterior low resection combined with terminal ileum enterostomy and they were further classified into mild group and severe group according to the scores of colonscopic examinations for DC. 16s-rDNA sequencing was carried out to analyze the diversity and and differences of intestinal flora in the intestinal lavage fluid of the two groups.Results: In retrospective study, we found that age, BMI, history of diabetes, and symptoms associated with the stoma state were the independent risk factors that affect DC severity (P<0.05). Meanwhile, age, BMI, history of diabetes and colonscopic score were found to be independent risk factors affecting the severity of diarrhea after ileostomy closure surgery(P&lt;0.05), which was consistent with our results of differentiating the severity of DC under endoscopy; In propsective oberservational study, 40 patients with low rectal cancer recruited by sample size calculation, 23 were in the mild group and 17 in the severe group. The results of 16s-rDNA sequencing showed that intestinal flora with high enrichment values primarily consisted of Bifidobacteriales and Prevotella in mild group, whereas that in the severe group consisted of Providencia and Dorea. The functional predictions on such two types of intestinal flora were mainly focused on lipid synthesis, glycan synthesis, metabolism, and amino acid metabolism pathways.Conclusion: After ileostomy closure surgery, a series of severe clinical symptoms might appear in DC patients. There are significant differences in local and systemic inflammatory responses, composition of intestinal flora between DC patients with different colonscopic scores, which provide a basis for the clinical interventional treatment for DC in patients with permanent stoma.

17 December 2025 in The Journal of Gene Medicine
Verified
Journal Article
Open access
JWJiexuan Wang
Jiexuan Wang
XYXin Yang
Xin Yang
XDXuan Dai
Xuan Dai
ZHZhiqian Hu
Zhiqian Hu
XLXinxing Li
Xinxing Li
Background: Gastric cancer (GC) is highly heterogeneous, and current prognostic models fail to fully capture tumor immune characteristics, limiting personalized treatment. This study introduces the Tumor Immune Environment Score (TIES), an immune‐based prognostic model designed to enhance risk stratification and predict response to immunotherapy. Methods: Transcriptomic and clinical data from seven GC cohorts, comprising a total of 1487 patients, were analyzed. The training cohort included GSE15459, GSE62254, GSE84433, and GSE13861, while the validation cohort comprised GSE26899, GSE26901, and TCGA‐STAD. Immune‐related gene signatures were quantified using ssGSEA and subsequently analyzed via LASSO and Cox regression. Clinical applicability was quantified using decision‐curve analysis (DCA) and reclassification metrics (category‐free NRI/IDI) for TIES versus TIES + pathological stage. Immunotherapy response was assessed using data from GSE183924, and its associations with immune characteristics, molecular alterations, and drug sensitivity were investigated. For experimental confirmation, we established a 12‐gene RT‐qPCR panel in 30 institutional GC specimens and computed a weighted qPCR surrogate (qTIES). Results: A high TIES was associated with worse OS (HR = 2.44, p < 0.001) and DFS (HR = 2.25, p < 0.001). TIES was an independent prognostic factor and demonstrated superior predictive accuracy compared to TNM staging (AUC = 0.75–0.79 vs. 0.61–0.64, p < 0.001). Integrating clinical‐pathological features with TIES significantly enhanced predictive performance (AUC = 0.75–0.78 vs. 0.61–0.63, p < 0.01). A low TIES was indicative of an immune‐inflamed subtype, characterized by a higher TMB ( p < 0.01) and a greater likelihood of response to immunotherapy (HR = 0.24, p = 0.014). TIES outperformed TIDE in predicting immunotherapy outcomes, achieving a higher OS C‐index (0.780 vs. 0.743) and DFS C‐index (0.664 vs. 0.610). At 3 years, TIES + stage yielded a greater net benefit than TIES alone across clinically relevant thresholds (DCA) and improved NRI/IDI.The qPCR panel reproduced axis biology (CSR/TGF‐βincreased with NK/Th2 decreased), correlated with pathological stage, stratified OS/DFS by Kaplan–Meier, and showed 3‐year discrimination. Conclusion: TIES represents a robust immune‐based prognostic tool for GC, facilitating improved risk stratification and immunotherapy response prediction. Its integration into clinical practice, particularly in combination with clinical‐pathological features, may enhance personalized treatment strategies and improve patient outcomes.